All posts of Dr. Laurie Sehn

Ibrutinib Plus R-CHOP in Patients with Previously Untreated Non-Germinal Centre B-Cell-like DLBCL

Oral presentation by Dr. Anas Younes    Standard treatment for advanced stage diffuse large B-cell lymphoma (DLBCL) is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). It is well understood that DLBCL is a heterogeneous entity, with patients with activated B-cell (ABC; as classified by gene expression profiling) or non-germinal centre B-cell (non-GCB; as classified by immunohistochemistry) […]

The AUGMENT Study with Lenalidomide and Rituximab in Patients with Relapsed/Refractory iNHL

Oral presentation by Dr. John P. Leonard Immunochemotherapy followed by rituximab maintenance is the standard of care in previously untreated patients with symptomatic follicular lymphoma (FL). Bendamustine and rituximab followed by 2 years of rituximab maintenance is the most commonly used initial therapy in Canada. Inevitably, most patients will relapse and require further therapy. Currently, […]

Acalabrutinib in Patients with Waldenström Macroglobulinemia

Oral presentation by: Dr. Roger Owen Acalabrutinib is a highly selective Bruton tyrosine kinase (BTK) inhibitor that has recently been approved by the Food and Drug Administration for patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Based on its higher selectivity for BTK than ibrutinib, it may have fewer off-target effects, which may […]

Lenalidomide plus Rituximab vs. Chemotherapy plus Rituximab in Patients with Previously Untreated Follicular Lymphoma

Oral presentation by: Dr. Nathan H. Fowler Immunochemotherapy induction followed by rituximab maintenance is the standard of care in previously untreated patients with symptomatic follicular lymphoma (FL). RELEVANCE is a randomized phase III trial comparing lenalidomide and rituximab (R2) versus rituximab plus chemotherapy (R-chemo) followed by rituximab maintenance in previously untreated patients with grade 1–3a […]

Venetoclax Plus Rituximab vs. Bendamustine Plus Rituximab in Patients with R/R CLL

Oral presentation by Dr. John F. Seymour The MURANO study is the first phase III trial of venetoclax, an oral selective inhibitor of BCL-2, in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). MURANO assessed the efficacy and safety of venetoclax plus rituximab (VR) vs. standard chemoimmunotherapy, bendamustine plus rituximab (BR). Patients were randomized (1:1) […]

Long-Term Follow-Up of the PRIMA Study with Rituximab Maintenance

Oral presentation by Dr. Gilles Andre Salles The PRIMA phase III study demonstrated a benefit in terms of progression-free survival (PFS) with the use of two years of rituximab maintenance after response to first-line rituximab and chemotherapy induction. In this abstract, Salles and colleagues report the long-term results of PRIMA. Patients with follicular lymphoma (FL) […]

Brentuximab Vedotin Plus Doxorubicin, Vinblastine, and Dacarbazine in Patients with Previously Untreated Stage III/IV HL

Oral presentation by Dr. Joseph M. Connors The Echelon-1 study was presented in the plenary session at this year’s ASH meeting. Echelon-1 was a nonblinded, open-label, randomized, multicentre, phase III study comparing brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) with the current standard of care, doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as […]